Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Eylea |
| Active Ingredient: | Aflibercept 40mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | Bayer New Zealand Limited |
| Manufacturers: | Bayer AG, Berlin, Germany Regeneron Pharmaceuticals Inc, New York, United States of America |
| Product: | Jardiance |
| Active Ingredient: | Empagliflozin 10mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Boehringer Ingelheim (NZ) Limited |
| Manufacturers: | Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany Boehringer Ingelheim Ellas AE, Koropi Attiki, Greece |
| Product: | Jardiance |
| Active Ingredient: | Empagliflozin 25mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Boehringer Ingelheim (NZ) Limited |
| Manufacturers: | Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany Boehringer Ingelheim Ellas AE, Koropi Attiki, Greece |
| Product: | Keytruda |
| Active Ingredient: | Pembrolizumab 25mg/mL |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
| Manufacturer: | MSD International GmbH t/a MSD Ireland (Carlow), Carlow, Ireland |
Dated this 14th day of February 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).